A Mitochondrion-Targeted NIR-II Modulator for Synergistic Ferroptosis-Immunotherapy
文献类型：期刊论文
| 作者 | Wang, Miao1,2; Ding, Qihang1,2,3,4,5; Su, Wuyue1,2,3,4,6; Luo, Min1,2; Yang, Runping7; Chen, Guopeng8; Wang, Qian8; Zhang, Nan8; Gao, Jialu1,2,3,4,6; Wang, Xiaofen1,2,3,4,6 |
| 刊名 | SMALL
 |
| 出版日期 | 2025-04-14 |
| 页码 | 13 |
| 关键词 | antitumor immunity activity ferroptosis immunogenic cell death mitochondria targeting NIR-II modulator |
| ISSN号 | 1613-6810 |
| DOI | 10.1002/smll.202501397 |
| 英文摘要 | Immune checkpoint inhibitors (ICIs) have limited clinical efficacy against gastric cancer (GC) due to the nonimmunogenic tumor microenvironment. Therefore, inducing immunogenic cell death (ICD) to reprogram the immunogenic landscape is essential. This study develops HD-FA nanoparticles by encapsulating a novel mitochondrion-targeted NIR-II modulator, HD, within DSPE-PEG-FA. HD-FA exhibits superior spatiotemporal resolution, robust tumor accumulation, and minimal adverse effects. Upon 808 nm laser irradiation, HD-FA generates reactive oxygen species, leading to ferroptosis and oxidative stress damage in GC cells by inhibiting the SLC7A11/GSH/GPX4 axis. HD-FA triggers ICD, resulting in antitumor activity not only in primary tumors but also in distant tumors. Moreover, HD-FA promotes dendritic cell maturation, increases the effector-memory T-cell frequency, and reduces the presence of myeloid-derived suppressor cells, thereby fostering enhanced antitumor immunity. This study presents the first report of a novel NIR-II modulator for GC immunogenic synergistic therapy with ICIs, marking significant advancements in the fight against GC. |
| WOS关键词 | IMMUNOGENIC CELL-DEATH ; PHOTODYNAMIC THERAPY ; CANCER ; PHOTOSENSITIZER |
| 资助项目 | National Key R&D Program of China ; National Natural Science Foundation of China[22477129] ; National Natural Science Foundation of China[82273796] ; Shenzhen Science and Technology Research Grant[JCYJ20240813111300001] ; Shenzhen Science and Technology Research Grant[JCYJ20220530140605012] ; Shenzhen Science and Technology Research Grant[JCYJ20230807090100002] ; Guangdong Basic and Applied Basic Research Foundation[2023A1515012649] ; Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University[ZNJC202315] ; Tibet Autonomous Region Science and Technology Plan Project Key Project[XZ202301ZY0014G] ; Natural Science Foundation of Shandong Province[ZR2023MB085] ; Shandong Laboratory Program[SYS202205] ; Hubei Provincial Natural Science Foundation of China[2022CFB810] ; [2023YFC3605500] |
| WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics |
| 语种 | 英语 |
| WOS记录号 | WOS:001465532500001 |
| 出版者 | WILEY-V C H VERLAG GMBH |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/317446]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Wei, Yongchang; Xiao, Yuling |
| 作者单位 | 1.Wuhan Univ, Hubei Canc Clin Study Ctr, Sch Pharmaceut Sci, Dept Radiat & Med Oncol,Zhongnan Hosp, Wuhan 430071, Peoples R China 2.Sch Pharmaceut Sci, Hubei Key Lab Tumor Biol Behav, Wuhan 430071, Peoples R China 3.Shanghai Inst Mat Med, Chinese Acad Sci, State Key Lab Drug Res, Shanghai 201203, Peoples R China 4.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Peoples R China 5.Korea Univ, Dept Chem, Seoul 02841, South Korea 6.Wuhan Univ, Shenzhen Inst, Shenzhen 518057, Peoples R China 7.Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Dermatol, Beijing 100048, Peoples R China 8.Wuhan Univ, Zhongnan Hosp, Dept Hematol, Wuhan 430071, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Miao,Ding, Qihang,Su, Wuyue,et al. A Mitochondrion-Targeted NIR-II Modulator for Synergistic Ferroptosis-Immunotherapy[J]. SMALL,2025:13. |
| APA | Wang, Miao.,Ding, Qihang.,Su, Wuyue.,Luo, Min.,Yang, Runping.,...&Xiao, Yuling.(2025).A Mitochondrion-Targeted NIR-II Modulator for Synergistic Ferroptosis-Immunotherapy.SMALL,13. |
| MLA | Wang, Miao,et al."A Mitochondrion-Targeted NIR-II Modulator for Synergistic Ferroptosis-Immunotherapy".SMALL (2025):13. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。